Neorecormon
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Anaemia
Conditions
Anaemia, Renal Transplantation, Kidney Failure
Trial Timeline
Apr 1, 2004 → May 1, 2010
NCT ID
NCT00396435About Neorecormon
Neorecormon is a approved stage product being developed by Roche for Anaemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00396435. Target conditions include Anaemia, Renal Transplantation, Kidney Failure.
What happened to similar drugs?
1 of 4 similar drugs in Anaemia were approved
Approved (1) Terminated (1) Active (2)
✅IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous PlaceboRafael HoldingsApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00396435 | Approved | Completed |
Competing Products
11 competing products in Anaemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DS-1093 + placebo | Daiichi Sankyo | Phase 1 | 29 |
| Hetrombopag Olamine Tablet | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Hetrombopag Olamine Tablet；Ciclosporin Soft Capsule | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| Hetrombopag Olamine Tablet | Jiangsu Hengrui Medicine | Phase 1 | 29 |
| SAR445088 | Sanofi | Phase 1 | 21 |
| BIVV020 | Sanofi | Phase 1 | 29 |
| G-CSF + Early retreatment with ATG | Sanofi | Phase 3 | 32 |
| rilzabrutinib + placebo | Sanofi | Phase 3 | 47 |
| Ferrum Lek® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Lek d.d., Slovenia) + MALTOFER® (iron (III) hydroxide polymaltosate), 100 mg chewable tablets (Vifor S.A., Switzerland) | Sandoz Group | Phase 3 | 37 |
| Ferric Maltol | Medpace | Phase 1 | 26 |
| IV trivalent saccharose hydroxide ferrous + Oral ferrous fumarate + Oral and intravenous Placebo | Rafael Holdings | Approved | 33 |